An open label, non-comparative study was carried out in 22 women over a total of five
cycles. After an untreated cycle, oral administration of 20 μg ethinyl estradiol (EE) with 50 μg …

The monophasic combination preparation containing 30 micrograms ethinyl estradiol and
75 micrograms gestodene was tested for contraceptive reliability, cycle control and …

Twenty-five healthy women volunteers were selected to evaluate ovulation inhibition by a
monophasic oral contraceptive preparation containing 75 micrograms gestodene and 30 …

The minimal effective dose of gestodene for inhibition of ovulation was studied in 30 female
volunteers. Daily doses of 10 μg to 50 μg gestodene were given orally for 21 days. A control …

Objective: To compare ovulation inhibition and ovarian activity with 21-day and 24-day
regimens of a low-dose combined oral contraceptive (COC) containing 60 μg of gestodene …

Ovulation inhibition by the monophasic oral contraceptive containing 75 μg of gestodene
and 30 wg of ethinyl estradiol was evaluated in 25 healthy volunteers for five cycles: a …

In a large and open prospective multicenter trial of 12,250 cycles from 2,378 women,
contraceptive efficacy, clinical tolerance and acceptability of a new monophasic …

The safety and efficacy of a low-dose monophasic oral contraceptive (OC) containing a new
progestogen, gestodene (GTD), combined with ethinyl estradiol (EE) is being investigated in …

The aim of this study was to compare contraceptive reliability, cycle control and tolerance of
an oral contraceptive containing 20 μg ethinylestradiol and 75 μg gestodene, with a …

The aim of this study was to compare contraceptive reliability, cycle control, and tolerance of
an oral contraceptive containing 20 μg ethinylestradiol (EE2) and 75 μg gestodene (GSD) …